Clinical Trial Update: A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial of Pyrotinib in advanced non-small cell lung cancer with HER2 mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Non Small Cell Lung | Phase 2 | Status: COMPLETED